How To Build The Future: Max Hodak

Why It Matters

Restoring vision validates BCI’s therapeutic potential and paves the way for a new class of neural implants that could eventually move from treating disability to enhancing everyday human capabilities.

Key Takeaways

• First clinical trial restores sight via retinal implant.
• BCI technology will diversify across multiple medical applications.
• Neuroplasticity enables adult patients to adapt to implants.
• Critical periods limit vision restoration for congenital blindness.
• Future BCIs may shift from therapeutic to consumer enhancements.

Summary

The episode features Max Hodak, co‑founder of Neuralink and founder of Science, discussing the latest breakthrough in brain‑computer interfaces: a 2 mm × 2 mm retinal implant that has already restored functional vision to more than 40 patients in a multi‑site European trial. The device, implanted behind the retina, receives visual data from a camera‑equipped glasses system and converts laser‑projected light into electrical stimulation, bypassing damaged photoreceptors. Hodak explains that this success marks the transition from incremental biotech to a true take‑off era for BCI, with multiple companies pursuing distinct modalities—visual, auditory, motor, and even neuromodulatory applications such as focus or sleep enhancement. He stresses the importance of neuroplasticity, noting that adult brains can quickly learn to control implanted neurons, while also acknowledging critical developmental windows that limit restoration for congenital blindness. Illustrative anecdotes include patients experiencing vivid hallucinations before the implant calibrates, and the rare case of conjoined twins sharing a thalamic bridge, suggesting that direct brain‑to‑brain communication is biologically plausible. Hodak also highlights the risk‑benefit calculus: early BCI deployments target severely disabled patients because the therapeutic gain outweighs surgical risk, but as bandwidth and bidirectional interfaces improve, broader, possibly consumer‑grade uses may emerge. The implications are profound. Regulatory approval of the retinal system could open a fast‑track pathway for other sensory prosthetics, while the broader BCI ecosystem may soon expand beyond medical necessity into performance‑enhancing and entertainment markets, reshaping healthcare economics and raising ethical questions about human augmentation.

Original Description

YC alum Max Hodak is the co-founder of Neuralink and founder of Science, a company building brain-computer interfaces that can restore sight.

Science has developed a tiny retinal implant that stimulates cells in the eye to help blind patients see again. More than 40 patients have already received the treatment in clinical trials, including one who recently read a full novel for the first time in over a decade.

In this episode of How to Build the Future, Max joined Garry to discuss how BCIs work, what it takes to engineer the brain, and why brain-computer interfaces may become one of the most important technologies of the next decade.

Chapters:

00:26 — The retinal chip helping blind patients see

01:51 — What brain-computer interfaces really are

03:37 — Could BCIs enhance intelligence?

05:44 — The brain’s incredible plasticity

09:23 — What it feels like to see with an implant

13:01 — Can we restore full human vision?

17:55 — Is the brain basically a computer?

24:59 — Max Hodak’s path into brain tech

28:57 — How Neuralink actually started

33:10 — How the brain represents information

39:47 — Bio-hybrid brain interfaces

44:32 — Building the company Science

51:27 — The future of BCIs and human longevity

Apply to Y Combinator: https://www.ycombinator.com/apply

Work at a startup: https://www.ycombinator.com/jobs